About us

Management

Image

Luc Dochez - Chief Executive Officer

Luc Dochez has been Chief Executive Officer of Tusk Therapeutics since May 2015. He joined Tusk from Prosensa Holding N.V. where he served as Chief Business Officer and Senior Vice President of Business Development for a period of seven years until its acquisition by BioMarin Pharmaceutical Inc. Earlier in his career, he served as Vice President of Business Development at TiGenix, Director Business Development at Methexis Genomics, and a consultant at Arthur D. Little. Luc holds a Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an MBA from Vlerick Management School (Belgium). Luc also serves on the Board of Directors of Erytech SA and Pharvaris BV.

Image

Dominic Smethurst - Chief Medical Officer

Dominic Smethurst is Chief Medical Officer at Tusk Therapeutics. He joined Tusk from Icon Plc where he was Vice President, Head of Oncology. He is a Cambridge-trained physician with over 14 years’ international industry experience and has had an extensive leadership career as Medical Director/Chief Medical Officer with companies including AstraZeneca, Amgen and Adaptimmune/Immunocore and has been pivotally involved in the registration of late stage drugs and product launches as well as re-aligning pipelines and managing companies through significant inflexion points.

Image

Kevin Moulder - Chief Development Officer

Kevin Moulder is Chief Development Officer of Tusk Therapeutics. He has had an extensive international career in antibody and biotherapeutics discovery and development in his previous roles as Vice President R&D at Domantis, Director, Medical Research at Biogen (USA) and Molecular Partners (CH) and Chief Scientific Officer at F-star and has been responsible for a large number of successful IND and CTA filings. Kevin has a Ph. D. in Immunology from the University of London and did a post doc at the National Institutes of Health (USA) on gamma delta T-cells.

Image

Anne Goubier - VP Immunology

Anne Goubier is Vice President Immunology at Tusk Therapeutics. She started her career at Merial (now Sanofi Animal Health), first as a veterinary scientist before rapidly progressing to head of the Immunology laboratory and of the adjuvant selection and validation platform. She has since dedicated her experience and expertise to human cancer immunotherapies research and development within small-sized companies including as Genticel and PX Biosolutions. Anne has a doctorate in Veterinary medicine and a Ph. D. in immunology from the University of Lyon.

Image

Paul Smith - VP Regulatory Affairs

Paul Smith is Vice President Regulatory Affairs at Tusk Therapeutics. He has over 20 years’ experience in the biotechnology field, most notably at Amgen where he provided regulatory leadership and strategic direction for European and International teams. Whilst at Amgen he was responsible for getting the first mAb EGFR inhibitor approved with a KRAS biomarker label for colorectal cancer and preparing the EU regulatory teams for the launch of a novel oncolytic virus and a bispecific T-cell engager. Prior to joining Tusk, Paul was leading the global regulatory team for an oncology business development acquisition in over 100 countries.

Image

Pascal Merchiers - VP R&D

Pascal Merchiers is Vice President of R&D at Tusk Therapeutics. He has over 15 years’ drug development experience and antibody expertise across a wide range of therapeutic areas and has held senior positions at IntroGene BV, Galapagos NV, Ablynx NV and Thrombogenics NV. Pascal has a Ph. D. in Medical sciences from the University of Leuven (Belgium).

Image

Matthew Hall - Chief Financial Officer

Matthew Hall is Chief Financial Officer at Tusk Therapeutics. He joined Tusk from Simbec-Orion Group, a boutique CRO, where he was CFO and prior to that spent five years as CFO at Sphere Medical Holding plc, an innovative point-of-care monitoring and diagnostic devices company. Previously Matthew was CFO at IS Pharma plc (now Sinclair Pharma plc), a specialist pharmaceutical company and he spent his earlier career in investment banking advising on M&A, IPOs, corporate financing and takeovers. He is a chartered accountant and holds a degree in economics.

Board

Luc Dochez

Luc Dochez has been Chief Executive Officer of Tusk Therapeutics since May 2015. He joined Tusk from Prosensa Holding N.V. where he served as Chief Business Officer and Senior Vice President of Business Development for a period of seven years until its acquisition by BioMarin Pharmaceutical Inc. Earlier in his career, he served as Vice President of Business Development at TiGenix, Director Business Development at Methexis Genomics, and a consultant at Arthur D. Little. Luc holds a Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an MBA from Vlerick Management School (Belgium). Luc also serves on the Board of Directors of Erytech SA and Pharvaris BV.

Image

George Golumbeski

George Golumbeski is currently Executive Vice President for Celgene Corporation, where he is recognized as one of the major innovators behind Celgene’s well-regarded collaboration strategy and tactics. In his nearly 25-year career in the sector, George has held many senior positions in R&D and Business Development. He is known globally within the biotechnology industry for his interest in leading-edge science, and his creativity in forging inter-company collaborations. The impact of George’s work in fostering innovation among biotech companies was recognized in 2014, when Fierce Biotech named him one of the 20 most influential people in the Biotechnology industry. George earned a BA in Biology from the University of Virginia and a Ph. D. in Genetics from the University of Wisconsin-Madison. George also serves on the Board of Directors of Tizona Therapeutics and the National Audubon Society.

Image

Terry Rosen

Terry Rosen is the CEO of Arcus Biosciences. He previously served as CEO of Flexus Biosciences, which was acquired by BMS in 2015. Prior to co-founding Flexus in October of 2013, Terry served as Vice President, Therapeutic Discovery, at Amgen and as the site head for Amgen South San Francisco, after having joined Amgen with the acquisition of Tularik in 2004. Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. He holds a BS in Chemistry from the University of Michigan and a Ph.D. in Organic Chemistry from the University of California, Berkeley. Terry serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology and Biology and Biological Engineering Chair’s Council and the California Life Sciences Association Board. Terry also serves on the Board of Directors of IDEAYA Biosciences.

Image

Eric K. Rowinsky

Eric K. Rowinsky is Executive Chairman and President of Rgenix, Inc and serves as Adjunct Professor of Medicine at New York University. Previously, Eric held various positions in biotechnology companies and has been the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics and Chief Medical Officer of Primrose Therapeutics. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated. From 1996 to 2004, Eric held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and was Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Eric was an associate professor of oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Eric has a BA in liberal Arts from New York University and completed his medical training from Vanderbilt University School of Medicine. Eric also serves on the Board of Directors of Biogen Inc., Fortress Biotech Inc., Navidea Biopharmaceuticals, Inc., BIND Therapeutics, Inc. and BioXcel Inc.

Image

Bart Van Hooland

Bart Van Hooland is Managing Partner at DROIA Oncology Ventures, a specialist venture capital investor, exclusively focused on oncology. DROIA, based in Luxembourg and Brussels, was co-founded by Bart in 2011. Prior to that, Bart worked at the Boston Consulting Group in Paris and was partner in a number of private holding companies. He has an MSc in Electronics from the University of Ghent and an MBA from INSEAD, Fontainebleau. Bart also serves on the Board of Directors of Bioncotech SL and NormOxys Inc.

Image

Janwillem Naesens

Janwillem Naesens is Partner at DROIA Oncology Ventures, an investor in early-stage oncology drug development companies, and currently serves on the Board of Directors of 6 biotech companies in Europe and the US. Before DROIA, Janwillem was Investment Manager at Waterland Private Equity, a European investment group providing growth capital to small and mid-sized companies. Janwillem started his career at McKinsey & Company in New York as a strategy consultant in life sciences and financial services and holds an MSc in Engineering from the University of Leuven and an MBA from INSEAD.

Image